STADA and Xbrane start launching Ximluci in Europe

Germany’s STADA Arzneimittel (SAZ: Xetra) and Sweden’s Xbrane Biopharma (Nasdaq Stockholm: XBRANE) are introducing Ximluci (ranibizumab) in several European countries to offer European ophthalmologists and their patients a cost-effective option to treat visual impairment, including neovascular or wet age-related macular degeneration (AMD).

The biosimilar was  approved by the European Commission in November last year as offering comparable quality, safety and efficacy in all the adult indications of the reference biologic, Lucentis, which is marketed by Swiss pharma major Novartis (NOVN: VX) in Europe and other markets, except the USA, where it is sold by Roche (ROG: SIX) .

Shipments of Ximluci, which is produced, filled, sterilized and packaged entirely within Europe, have begun in several countries, and launch activities are underway in many others.